# US 12,215,316 B2 · Materials and methods for treatment of usher syndrome type 2A

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,316 B2
- Document ID: US12215316B2
- Status: Granted
- Kind: B2
- Application number: 17/360,578
- Filed: 2021-06-28
- Published: 2021-12-30
- Granted: 2025-02-04
- Earliest claimed: 2017-12-21
- Assignees: Crispr Therapeutics AG; Bayer HealthCare LLC
- Applicants: Crispr Therapeutics AG; Bayer Healthcare LLC
- Inventors: Albena Kantardzhieva; Akiko Noma; Abraham Scaria
- Web page: https://patentgrep.com/patent/US12215316B2

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61P 27/00: Drugs for disorders of the senses
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.

## Claims

### Claim 1

An in vivo method for treating a patient with Usher Syndrome Type 2A, the method comprising: editing an USH2A gene containing an IVS40 mutation in eye cells of the patient, wherein the editing comprises introducing into the eye cell one or more DNA endonucleases selected from the group consisting of Cas9 and Cpf1 endonucleases and nickases and one or more guide ribonucleic acids (gRNAs) comprising a spacer sequence complementary to a sequence with or near intron 40 of the USH2A gene to effect one or more SSBs or DSBs within or near intron 40 or the USH2A gene the results in a correction and results in restoration of usherin protein function.

### Claim 2

A gRNA or sgRNA comprising a nucleotide sequence set forth in SEQ ID NO: 5321, SEQ ID NO: 5323, SEQ ID NO: 5325, SEQ ID NO: 5327, or SEQ ID NO: 5328.

### Claim 3

A gRNA or sgRNA comprising;
a) SEQ ID NO: 5321 and any one of SEQ ID NOs: 5267-5269;
b) SEQ ID NO: 5323 and any one of SEQ ID NOs: 5267-5269;
c) SEQ ID NO: 5325 and any one of SEQ ID NOs: 5267-5269;
d) SEQ ID NO: 5327 and any one of SEQ ID NOs: 5267-5269; or
e) SEQ ID NO: 5328 and any one of SEQ ID NOs: 5267-5269.

### Claim 4

A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of a Cas9 endonuclease and nickases and a Cfp1 endonuclease and a gRNA or sgRNA to eye cells of the patient, wherein the gRNA or sgRNA comprises SEQ ID NO: 5321, SEQ ID NO: 5323, SEQ ID NO: 5325, SEQ ID NO: 5327, or SEQ ID NO: 5328.

### Claim 5

A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of a Cas9 endonuclease and nickases and a Cfp1 endonuclease and a gRNA or sgRNA to eye cells of the patient, wherein the gRNA or sgRNA comprises
a) SEQ ID NO: 5321 and any one of SEQ ID NOs: 5267-5269;
b) SEQ ID NO: 5323 and any one of SEQ ID NOs: 5267-5269;
c) SEQ ID NO: 5325 and any one of SEQ ID NOs: 5267-5269;
d) SEQ ID NO: 5327 and any one of SEQ ID NOs: 5267-5269; or
e) SEQ ID NO: 5328 and any one of SEQ ID NOs: 5267-5269.

### Claim 6

A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of Cas9 and Cfp1 endonucleases and nickases and a first gRNA or sgRNA and second gRNA or sgRNA to eye cells of the patient, wherein
a) the first gRNA or sgRNA comprises SEQ ID NO: 5295 and the second gRNA or sgRNA comprises SEQ ID NO: 5279;
b) the first gRNA or sgRNA comprises SEQ ID NO: 5294 and the second gRNA or sgRNA comprises SEQ ID NO: 5300;
c) the first gRNA or sgRNA comprises SEQ ID NO: 5295 and the second gRNA or sgRNA comprises SEQ ID NO: 5300;
d) the first gRNA or sgRNA comprises SEQ ID NO: 5290 and the second gRNA or sgRNA comprises SEQ ID NO: 5300; or
e) the first gRNA or sgRNA comprises SEQ ID NO: 5277 and the second gRNA or sgRNA comprises SEQ ID NO: 5300.

### Claim 7

A method for treating a patient with an USH2A gene containing an IVS40 mutation, the method comprising: administering an endonuclease selected from the group consisting of Cas9 and Cfp1 endonucleases and nickases and a first gRNA or sgRNA and second gRNA or sgRNA to eye cells of the patient, wherein
a) a first gRNA or sgRNA comprises SEQ ID NO: 5452 and the second gRNA or sgRNA comprises SEQ ID NO: 5449;
b) a first gRNA or sgRNA comprises SEQ ID NO: 5453 and the second gRNA or sgRNA comprises SEQ ID NO: 5449;
c) a first gRNA or sgRNA comprises SEQ ID NO: 5455 and the second gRNA or sgRNA comprises SEQ ID NO: 5457;
d) a first gRNA or sgRNA comprises SEQ ID NO: 5452 and the second gRNA or sgRNA comprises SEQ ID NO: 5451; or
e) a first gRNA or sgRNA comprises SEQ ID NO: 5448 and the second gRNA or sgRNA comprises SEQ ID NO: 5449.